title: Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons.
abstract: The cannabinoid CB1 receptor which is densely located in the basal ganglia is known to participate in the regulation of movement. The present study sought to determine the mechanisms underlying the effect of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) on neurons in the substantia nigra pars compacta (SNpc) using single-unit extracellular recordings in anesthetized rats. Administration of Delta(9)-THC (0.25-2 mg/kg, i.v.) increased the firing rate of SNpc neurons (maximal effect: 33.54+/-6.90%, n=8) without modifying other firing parameters (coefficient of variation and burst firing). This effect was completely blocked by the cannabinoid receptor antagonist rimonabant (0.5 mg/kg, i.v.). In addition, the blockade of excitatory amino acids receptors by kynurenic acid (0.5 microM, i.c.v.) or a chemical lesion of the subthalamic nucleus (STN) with ibotenic acid abolished Delta(9)-THC effect. These results indicate that CB1 receptor activation modulates SNpc neuronal activity by an indirect mechanism involving excitatory amino acids, probably released from STN axon terminals in the SNpc.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of the Basque Country, E-48940 Leioa, Vizcaya, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Morera-Herreras
authors.forename: J A
authors.initials: JA
authors.lastname: Ruiz-Ortega
authors.forename: S
authors.initials: S
authors.lastname: Gómez-Urquijo
authors.forename: L
authors.initials: L
authors.lastname: Ugedo
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology*; D018690:Excitatory Amino Acid Agonists / Q000009:adverse effects; D007051:Ibotenic Acid / Q000009:adverse effects; D007736:Kynurenic Acid / Q000009:adverse effects; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077285:Rimonabant; D013378:Substantia Nigra / Q000166:cytology; D020531:Subthalamic Nucleus / Q000293:injuries / Q000502:physiology*
chemical_list: D018491:Dopamine Agonists; D018690:Excitatory Amino Acid Agonists; D010880:Piperidines; D011619:Psychotropic Drugs; D011720:Pyrazoles; D007051:Ibotenic Acid; D013759:Dronabinol; D007736:Kynurenic Acid; D001058:Apomorphine; D000077285:Rimonabant; D004298:Dopamine